+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 House Dust Mite Allergy Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767358
  • Report
  • April 2019
  • Region: Global
  • 142 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Allergy Therapeutics Plc
  • CSL Ltd
  • Japan Tobacco Inc
  • Kuros Biosciences AG
  • Lofarma SpA
  • Merck & Co Inc
  • MORE
The global clinical trial report- “2019 House Dust Mite Allergy Clinical Trials Study” provides complete list of trials completed, ongoing and planned for House Dust Mite Allergy. It presents in-depth analysis of House Dust Mite Allergy clinical trials across markets and companies. The research work is for providing complete understanding into trends in House Dust Mite Allergy.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the House Dust Mite Allergy clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of House Dust Mite Allergy

The research work is prepared through extensive and continuous research on House Dust Mite Allergy trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering House Dust Mite Allergy patients are identified
  • The report includes panorama of House Dust Mite Allergy clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on House Dust Mite Allergy clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergy Therapeutics Plc
  • CSL Ltd
  • Japan Tobacco Inc
  • Kuros Biosciences AG
  • Lofarma SpA
  • Merck & Co Inc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 House Dust Mite Allergy Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 House Dust Mite Allergy Clinical Trials by Region
2.2.2 Average Enrollment of House Dust Mite Allergy Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for House Dust Mite Allergy Treatment, 2019

3. Region wise House Dust Mite Allergy Clinical Trials
3.1 Asia Pacific House Dust Mite Allergy Clinical Trials by Country
3.2 Europe House Dust Mite Allergy Clinical Trials by Country
3.3 North America House Dust Mite Allergy Clinical Trials by Country
3.4 Middle East and Africa House Dust Mite Allergy Clinical Trials by Country
3.5 South and Central America House Dust Mite Allergy Clinical Trials by Country

4. House Dust Mite Allergy Clinical Trial Trends
4.1 Start Year wise House Dust Mite Allergy Clinical Trials
4.2 Phase wise House Dust Mite Allergy Clinical Trials
4.3 Trial Status wise House Dust Mite Allergy Clinical Trials
4.4 Trial Type wise House Dust Mite Allergy Clinical Trials

5. House Dust Mite Allergy Average Enrollment Trends
5.1 Average Enrollment in House Dust Mite Allergy Trials by Year
5.2 Average Enrollment in House Dust Mite Allergy Trials by Phase
5.3 Average Enrollment in House Dust Mite Allergy Trials by Status
5.4 Average Enrollment in House Dust Mite Allergy Trials by Type of Trial

6. Companies Participating in House Dust Mite Allergy Clinical Trials
6.1 House Dust Mite Allergy Trials by Sponsor Type
6.2 House Dust Mite Allergy Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 House Dust Mite Allergy Trials- Phase 1
7.2 House Dust Mite Allergy Trials- Phase 2
7.3 House Dust Mite Allergy Trials- Phase 3
7.4 House Dust Mite Allergy Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: House Dust Mite Allergy Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Figure 5: Europe - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Figure 7: North America - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Figure 9: House Dust Mite Allergy Clinical Trials by Phase
Figure 10: House Dust Mite Allergy Clinical Trials by Trial Status
Figure 11: House Dust Mite Allergy Clinical Trials by Type
Figure 12: House Dust Mite Allergy Clinical Trials by Sponsor Type
Figure 13: House Dust Mite Allergy Clinical Trials by Leading Sponsors
Figure 14: House Dust Mite Allergy Average Enrollment by Phase
Figure 15: House Dust Mite Allergy Average Enrollment by Trial Status
Figure 16: House Dust Mite Allergy Average Enrollment by Type
Figure 17: House Dust Mite Allergy- Average Enrolment by Type of Sponsors
Figure 18: House Dust Mite Allergy- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: House Dust Mite Allergy Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Table 5: Europe - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Table 7: North America - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Table 8: South and Central America - Country wise House Dust Mite Allergy Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: House Dust Mite Allergy Average Enrollment by Phase
Table 15: House Dust Mite Allergy Average Enrollment by Trial Status
Table 16: House Dust Mite Allergy Average Enrollment by Type
Table 17: House Dust Mite Allergy- Average Enrolment by Type of Sponsors
Table 18: House Dust Mite Allergy- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergy Therapeutics Plc
  • Circassia Pharmaceuticals Plc
  • CSL Ltd
  • Droege International Group AG
  • Japan Tobacco Inc
  • Kuros Biosciences AG
  • Lofarma SpA
  • Merck & Co Inc
  • Stallergenes Greer plc
  • The Lundbeck Foundation
Note: Product cover images may vary from those shown
Adroll
adroll